ClinicalTrials.gg
RecruitingNCT06033378BFBPUpdated Mar 13, 2025

Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage.

An interventional study of Blood pressure elevation in Blood Pressure, Subarachnoid Hemorrhage and Aneurysm Cerebral, sponsored by Umeå University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Umeå University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Subarachnoid Hemorrhage with a site in Sweden — 3 open to participants now, 4 under way, none of them phase 3. Subarachnoid Hemorrhage · Sweden.

Started
2023
the only one that year
No phase
2 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Umeå University

Among the 10 studies in Subarachnoid Hemorrhage with a site in Sweden, this one is the only one that started in 2023, is one of 2 with no phase, and was the 8th registered.

Subarachnoid Hemorrhage

513 studies on the registry are indexed under Subarachnoid Hemorrhage; 131 are open to participants now.

Browse Subarachnoid Hemorrhage studies →

Open to participants now

3 of the 10 studies in Subarachnoid Hemorrhage with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 92 Subarachnoid Hemorrhage studies recruiting now, 58 (63%) set no upper age limit and 5 (5%) stop at 75 or younger; 8 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Subarachnoid Hemorrhage with a site in Sweden, or all of them as a file.
02

Study summary

An MRI study to examine the relationship between blood pressure and cerebral blood flow in patients with subarachnoidal hemorrhage and suspect or verified vasospasm.

Read the detailed description

Subarachnoidal hemorrhage (SAH) is a type of stroke with high mortality rates and often requires care at the intensive care unit. Cerebral blood flow (CBF) needs to be ensured so that the brain receives optimal nourishment, and this is largely controlled by regulating blood pressure (BP) using medications that affect the heart and blood vessels. Approximately 3-7 days after SAH onset, vasospasm (SAH-V) can occur. Treatment usually includes maintaining blood pressure (BP) above a certain threshold to achieve adequate cerebral blood flow (CBF). An important component of raising BP is increasing vascular resistance using vasoconstrictive medications, which paradoxically can decrease CBF.

The study objective is to investigate the correlation between BP changes and their impact on CBF in patients with suspect or verified SAH-V using MRI.

To achieve this purpose, the investigators plan to examine the relationship between BP and CBF in patients with SAH-V who require neuro-intensive care. To measure CBF, two techniquis will be used: phase-contrast MRI and arterial spin labeling.

Flow measurement with MRI:

  1. Baseline images will be acquired at baseline blood pressure.
  2. Mean arterial pressure (MAP) will be increased using norepinephrine. New images will be acquired when MAP is increased by approximately 20-30% from the baseline.

All BP levels will be maintained within clinically acceptable ranges. All data will be recorded in the patient's medical record, and MRI images will be processed at a later stage.

03

Conditions studied

  • Blood Pressure
  • Subarachnoid Hemorrhage
  • Aneurysm Cerebral

Keywords

  • magnetic resonance imaging
  • norepinephrine
  • blood flow
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Coiled or clipped aneurysm
  • Suspected or confirmed vasospasm

Exclusion criteria

Exclusion Criteria:

  • >30
  • Pregnancy
  • Pacemaker or other MRI
  • Severe congestive heart failure ( III-IV) or cardiac arrhythmia.
  • Severe respiratory failure or FiO2 >0.6
  • Severe kidney failure
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cerebral blood flow

    Change in cerebral blood flow with increased systemic blood pressure

    Other: Blood pressure elevation

Interventions

  • OtherBlood pressure elevation

    Increasing systemic blood pressure for measurement of cerebral blood flow changes

06

What researchers measure

Primary outcomes

  1. Cerebral blood flow

    mL/min as measured by MRI

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 59 non-industry interventional studies with no phase under Subarachnoid Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 69. This study's planned 48 months is above that.

Counting every sponsor, half of 69 studies reached it within 32 months; a quarter within 20 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2023
First posted
Sep 13, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06033378
Lead sponsor
Umeå University
Collaborators
Region Västerbotten
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Sep 1, 2023
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Mar 13, 2025

Study contacts

Laleh Zarrinkoob, MD, PhD
Contact
laleh.zarrinkoob@umu.se
+46707567067
Laleh Zarrinkoob
principal investigator · Region Västerbotten

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion